PharmAbcine (A208340) Stock Overview
A clinical-stage biotech company, develops human therapeutic monoclonal antibody (mAb) for the treatment of neovascular disorders, tumors, and other medically unmet diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A208340 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
PharmAbcine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩173.00 |
| 52 Week High | ₩305.00 |
| 52 Week Low | ₩120.00 |
| Beta | 0.83 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -94.12% |
| 5 Year Change | -98.95% |
| Change since IPO | -99.32% |
Recent News & Updates
Shareholder Returns
| A208340 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -20.6% | -5.8% | 3.3% |
| 1Y | n/a | 38.7% | 89.2% |
Return vs Industry: Insufficient data to determine how A208340 performed against the KR Biotechs industry.
Return vs Market: Insufficient data to determine how A208340 performed against the KR Market.
Price Volatility
| A208340 volatility | |
|---|---|
| A208340 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A208340's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: Insufficient data to determine A208340's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 39 | ByeongIk Kim | www.pharmabcine.com |
PharmAbcine Inc., a clinical-stage biotech company, develops human therapeutic monoclonal antibody (mAb) for the treatment of neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for various spectrum of indications from oncology, immuno-oncology, ophthalmology, and pulmonology. The company also develops TTAC0001, an anti-angiogenic that neutralizes the VEGF/VEGFR2 pathway; PMC-309, a monoclonal antibody that targets the negative immune checkpoint human VISTA; PMC-402, a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization for solid tumors; and PMC-403, a monoclonal antibody that targets the human TIE2, which regulate the angiogenesis and vessel maturation in endothelial cells.
PharmAbcine Inc. Fundamentals Summary
| A208340 fundamental statistics | |
|---|---|
| Market cap | ₩13.39b |
| Earnings (TTM) | ₩1.13b |
| Revenue (TTM) | ₩15.19b |
Is A208340 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A208340 income statement (TTM) | |
|---|---|
| Revenue | ₩15.19b |
| Cost of Revenue | ₩8.92b |
| Gross Profit | ₩6.27b |
| Other Expenses | ₩5.14b |
| Earnings | ₩1.13b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.12 |
| Gross Margin | 41.28% |
| Net Profit Margin | 7.45% |
| Debt/Equity Ratio | 0% |
How did A208340 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/23 08:37 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmAbcine Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.